Sylvester Comprehensive Cancer Center, University of Miami | Strategic Alliance Partners

Lenalidomide plus luspatercept demonstrated safety, tolerability, and efficacy in patients with non-del(5q) myelodysplastic syndrome.

Sangeetha Venugopal, MD, MS, discusses factors that inform JAK inhibitor selection in myelofibrosis.

A person’s “biological age” may be a hidden factor in their risk of colorectal cancer before the age of 50.

Mikkael A. Sekeres, MD, discusses the results of combining luspatercept and lenalidomide in lower-risk, non–5q deletion myelodysplastic syndromes.

Janaki Neela Sharma, MD, discusses how data from EV-302 further defined the role of frontline enfortumab vedotin plus pembrolizumab in bladder cancer.

Justin M. Watts, MD, discusses the potential advantages of the oral small molecule BET inhibitor INCB057643 in advanced myelofibrosis.

Cindy M. Pabon, MD, highlights key findings and the clinical implications of 3 trials addressing questions in gastric and gastroesophageal cancer.

Janaki Neela Sharma, MD, discusses the implications of treatment advances in the front line for patients with advanced bladder cancer.

Janaki Neela Sharma, MD, discusses CheckMate 901, and where nivolumab plus chemotherapy fits into the advanced urothelial cancer treatment paradigm.

Janaki Neela Sharma, MD, discusses takeaways from the Sylvester Comprehensive Cancer Center 2024 Annual Oncology Update.

Janaki Neela Sharma, MD, discusses which trials have shifted the therapeutic paradigm for patients with urothelial cancer.

Janaki Neela Sharma, MD, discusses the road to FDA approval for enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

Janaki Neela Sharma, MD, discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced/metastatic bladder cancer.

Cindy Medina Pabon, MD, discusses the clinical relevance of the FDA approval of zolbetuximab for CLDN18.2-positive gastric or GEJ adenocarcinoma.

Higher breast cancer rates among Caribbean women may be linked to shifting patterns in their reproductive health according to data from a Sylvester Comprehensive Cancer Center study.

Samuel A. Kareff, MD, MPH, shares his reflections on the benefits, challenges, and critical elements of effective mentorship in hematology/oncology.

Dr Kareff discusses the intersections between early-phase clinical research and meaningful mentorship experiences during oncology/hematology fellowship.

A CD44 and total protein level detecting oral rinse-based test showed promise in identifying disease recurrence for patients with head and neck cancer.

Racial/ethnic minorities are often diagnosed with lung cancer at later stages than White patients but that disadvantage is smaller in Hispanic populations.

Ryan Hood, BA, discusses a study investigating the association between BRCA1/2 pathogenic variants and primary tumor location in pancreatic cancer.

Justin M. Watts, MD, discusses the final 5-year results of the 2102-HEM-101 trial of olutasidenib in patients with IDH1-mutated acute myeloid leukemia.

Steven Chen, PhD, and colleagues identified a 10-gene biomarker that may predict benefit with adjuvant chemotherapy in stage II/III colon cancer.

C. Ola Landgren, MD, PhD, discusses standard treatment approaches and the advantages of quadruplet regimens in newly diagnosed multiple myeloma.

Justin M. Watts, MD, discusses the design and purpose of a phase 1 trial evaluating INCB057643 in myelofibrosis and other advanced myeloid neoplasms.

C. Ola Landgren, MD, PhD, highlights how therapeutic improvements with quadruplet regimens will benefit all patients with newly diagnosed multiple myeloma.

C. Ola Landgren, MD, PhD, discusses the use of quadruplet regimens in patients with newly diagnosed multiple myeloma.

Justin M. Watts, MD, discusses phase 1 efficacy and safety data for the oral BET inhibitor INCB057643 in advanced myelofibrosis.

Mikkael A. Sekeres, MD, discusses a subgroup analysis of treatment with imetelstat in patients with low-to intermediate-1–risk myelodysplastic syndrome.

Mikkael A. Sekeres, MD, discusses the FDA approval of imetelstat for patients with low- to intermediate-1–risk MDS, highlighting data from a subanalysis.